Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-B3234 in Advanced Cancer
NCT02996838Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tunlametinib in solid tumor (advanced stage), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose at 48 weeks, Dose-Limiting Toxicity at 4 weeks and 5 more. Status: unknown.
02
Drugs
tunlametinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02996838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02996838.